Sopharma AD-Sofia (FRA:3JR) PE Ratio: 8.89 (As of Jul. 05, 2026) — 51% Below Median


FRA:3JR Sopharma AD-Sofia FRA:3JR
65 GF Score
Price €1.84
GF Value €3.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia PE Ratio?

Sopharma AD-Sofia FRA:3JR +6.36% 65 PE Ratio is 8.89 as of Jul. 05, 2026, which is 51% below its 10-year median of 17.98. GuruFocus rates FRA:3JR with a GF Score™ of 65/100 and a GF Value™ of €3.02 (Possible Value Trap). The stock has 4 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-05), Sopharma AD-Sofia's share price is €1.84. Sopharma AD-Sofia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21. Therefore, Sopharma AD-Sofia's PE Ratio for today is 8.89.

During the past 13 years, Sopharma AD-Sofia's highest PE Ratio was 94.59. The lowest was 6.24. And the median was 17.98.

Sopharma AD-Sofia's EPS (Diluted) for the three months ended in Mar. 2026 was €0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21.

As of today (2026-07-05), Sopharma AD-Sofia's share price is €1.84. Sopharma AD-Sofia's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €0.19. Therefore, Sopharma AD-Sofia's PE Ratio without NRI ratio for today is 9.48.

During the past 13 years, Sopharma AD-Sofia's highest PE Ratio without NRI was 64.69. The lowest was 5.87. And the median was 18.30.

Sopharma AD-Sofia's EPS without NRI for the three months ended in Mar. 2026 was €0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €0.19.

During the past 12 months, Sopharma AD-Sofia's average EPS without NRI Growth Rate was 61.70% per year.

During the past 13 years, Sopharma AD-Sofia's highest 3-Year average EPS without NRI Growth Rate was 41.10% per year. The lowest was -19.20% per year. And the median was -3.00% per year.

Sopharma AD-Sofia's EPS (Basic) for the three months ended in Mar. 2026 was €0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.21.

Back to Basics: PE Ratio


Sopharma AD-Sofia  (FRA:3JR) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Sopharma AD-Sofia PE Ratio Related Terms


Sopharma AD-Sofia PE Ratio Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia PE Ratio Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.32 15.43 16.30 24.70 N/A

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.20 43.37 16.55 N/A 8.45

FRA:3JR vs MCK, CAH, COR: PE Ratio Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sopharma AD-Sofia PE Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's PE Ratio falls into.


FRA:3JR
65GF Score
Sopharma AD-Sofia FRA:3JR
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Sopharma AD-Sofia's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=1.84/0.207
=8.89

Sopharma AD-Sofia's Share Price of today is €1.84.
Sopharma AD-Sofia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.21.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 8.89 mean?
Sopharma AD-Sofia (FRA:3JR) has a PE Ratio of 8.89 as of Jul. 05, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Sopharma AD-Sofia and its competitors. This is 51% below median its historical median of 17.98. Over the past decade, Sopharma AD-Sofia's PE Ratio has ranged from 6.24 to 94.59.
Is Sopharma AD-Sofia's PE Ratio too high?
Sopharma AD-Sofia's current PE Ratio of 8.89 is 51% below median its 10-year median of 17.98. Over the past 10 years, this metric has ranged from a low of 6.24 to a high of 94.59. Overall, Sopharma AD-Sofia has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's PE Ratio compare to MCK and CAH?
Sopharma AD-Sofia's PE Ratio of 8.89 can be compared against companies in the Medical Distribution industry. Historically, Sopharma AD-Sofia's own PE Ratio has ranged from 6.24 to 94.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Distribution company?
A good PE Ratio depends on the Medical Distribution industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current PE Ratio is 8.89, which is 51% below median its own 10-year median of 17.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Possible Value Trap. The stock's GF Value™ is €3.02, compared to a current price of €1.84 — trading 39.1% below its estimated fair value. The current PE Ratio is 8.89, which is 51% below median its 10-year median of 17.98. Sopharma AD-Sofia's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current PE Ratio is 8.89 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of €1.84 is trading 39.1% below its estimated GF Value™ of €3.02. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for FRA:3JR:

  • PE Ratio: 8.89 (51% below median its 10-year median of 17.98)
  • GF Value™: €3.02 vs. price of €1.84 (39.1% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sopharma AD-Sofia Business Description

Other Exchanges SPH:PolandSFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
65GF Score

Get the complete analysis for FRA:3JR

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price
€3.02
GF Value